Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Doramectin. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Hydrocodone | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Magnesium sulfate | The therapeutic efficacy of Doramectin can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Doramectin may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Mirtazapine | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Orphenadrine | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Pramipexole | Doramectin may increase the sedative activities of Pramipexole. |
| Ropinirole | Doramectin may increase the sedative activities of Ropinirole. |
| Rotigotine | Doramectin may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Doramectin. |
| Sodium oxybate | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Thalidomide | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of Doramectin can be increased when used in combination with Yohimbine. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Doramectin. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Doramectin. |
| Alfentanil | The serum concentration of Alfentanil can be increased when it is combined with Doramectin. |
| Buspirone | The metabolism of Buspirone can be decreased when combined with Doramectin. |
| Carbamazepine | The metabolism of Carbamazepine can be decreased when combined with Doramectin. |
| Cisapride | The serum concentration of Cisapride can be increased when it is combined with Doramectin. |
| Disopyramide | Doramectin may increase the QTc-prolonging activities of Disopyramide. |
| Estazolam | The serum concentration of Estazolam can be increased when it is combined with Doramectin. |
| Quinine | The serum concentration of Quinine can be increased when it is combined with Doramectin. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Doramectin. |
| Repaglinide | The serum concentration of Repaglinide can be increased when it is combined with Doramectin. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Doramectin. |
| Temsirolimus | The metabolism of Temsirolimus can be decreased when combined with Doramectin. |
| Terfenadine | The serum concentration of Terfenadine can be increased when it is combined with Doramectin. |
| Triazolam | The serum concentration of Triazolam can be increased when it is combined with Doramectin. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Doramectin. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Doramectin. |
| Fentanyl | The risk or severity of CNS depression can be increased when Fentanyl is combined with Doramectin. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Doramectin. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Doramectin. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Doramectin. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Doramectin. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Doramectin. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Doramectin. |
| Mefloquine | The therapeutic efficacy of Doramectin can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Doramectin can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Doramectin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Doramectin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Doramectin. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Doramectin. |
| Alprazolam | The serum concentration of Alprazolam can be increased when it is combined with Doramectin. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Doramectin. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Doramectin. |
| (R)-warfarin | The serum concentration of (R)-warfarin can be increased when it is combined with Doramectin. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Doramectin. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Doramectin. |
| (S)-Warfarin | The serum concentration of (S)-Warfarin can be increased when it is combined with Doramectin. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Doramectin. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Doramectin. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Doramectin. |
| Telaprevir | The serum concentration of Telaprevir can be increased when it is combined with Doramectin. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Doramectin. |
| Ethanol | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Doramectin may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Doramectin. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Doramectin is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Doramectin is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Doramectin is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Doramectin is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Doramectin is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Doramectin is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Doramectin is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Doramectin is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Doramectin is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Doramectin is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Doramectin is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Doramectin is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Doramectin is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Doramectin is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Doramectin is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Doramectin is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Doramectin is combined with Alaproclate. |
| Vintafolide | The serum concentration of Vintafolide can be increased when it is combined with Doramectin. |
| Vincamine | The serum concentration of Vincamine can be increased when it is combined with Doramectin. |
| Acetyldigitoxin | The serum concentration of Acetyldigitoxin can be increased when it is combined with Doramectin. |
| Deslanoside | The serum concentration of Deslanoside can be increased when it is combined with Doramectin. |
| Ouabain | The serum concentration of Ouabain can be increased when it is combined with Doramectin. |
| Oleandrin | The serum concentration of Oleandrin can be increased when it is combined with Doramectin. |
| Cymarin | The serum concentration of Cymarin can be increased when it is combined with Doramectin. |
| Proscillaridin | The serum concentration of Proscillaridin can be increased when it is combined with Doramectin. |
| Metildigoxin | The serum concentration of Metildigoxin can be increased when it is combined with Doramectin. |
| Lanatoside C | The serum concentration of Lanatoside C can be increased when it is combined with Doramectin. |
| Gitoformate | The serum concentration of Gitoformate can be increased when it is combined with Doramectin. |
| Acetyldigoxin | The serum concentration of Acetyldigoxin can be increased when it is combined with Doramectin. |
| Peruvoside | The serum concentration of Peruvoside can be increased when it is combined with Doramectin. |